Cassava Sciences (SAVA) announced the retirement of James Kupiec, chief medical officer, effective May 9. The company also appointed Jack Moore as senior VP, clinical development, reporting to Rick Barry, CEO.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Biotech Alert: Searches spiking for these stocks today
- Cassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpoint
- Cassava Sciences to resume trading at 8:35 am ET
- Cassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’s
- Cassava Sciences down 12% after simufilam doesn’t hit Alzheimer’s trial endpoint
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue